<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This study was aimed to investigate the immunologic characteristics of <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts-II (<z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB-II</z:e>) which belongs to a new subtype of World Health Organization (WHO) classification of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and to screen out the independent immunologic prognostic factors of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>35 cases of adult patients with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were investigated </plain></SENT>
<SENT sid="2" pm="."><plain>The immunofluorescent analysis by multiparameter flow cytometry was performed at the double gating of CD45/SSC to determine the immunophenotype of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cells in <z:hpo ids='HP_0000001'>all</z:hpo> cases </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were followed up </plain></SENT>
<SENT sid="4" pm="."><plain>47 cases of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) M1, 51 cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M(2) and 38 cases of <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (ALL) were selected as control </plain></SENT>
<SENT sid="5" pm="."><plain>Software SPSS 13.0 was applied to analyze <z:hpo ids='HP_0000001'>all</z:hpo> the related data </plain></SENT>
<SENT sid="6" pm="."><plain>The results showed that the positive expression rate of HLA-DR in <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB-II</z:e> was 100%, which was high in sensitivity and specificity </plain></SENT>
<SENT sid="7" pm="."><plain>CD13 (94.74%), CD33 (84.21%) and CD117 (78.95%) were also highly expressed in <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB-II</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>CD13 in <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB-II</z:e> was significantly higher than that in refractory cytopenia with or without multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (RA/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e>) (p &lt; 0.01) and REAB-I (p &lt; 0.05); CD33, CD117 (p &lt; 0.05) and stem cell antigen CD34 (p &lt; 0.01) in <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB-II</z:e> were significantly higher than that in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e> (p &lt; 0.01), but no statistically significant difference was found as compared with <z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB-I</z:e> (p &gt; 0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>Compared with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M(1) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M(2), no significant difference of CD13 and CD117 in <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB-II</z:e> was found (p &gt; 0.05) </plain></SENT>
<SENT sid="10" pm="."><plain>CD33 (p &lt; 0.01) and CD34 (p &lt; 0.05) were significantly lower than that in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M(1), but no significant difference was found as compared with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M(2) (p &gt; 0.05); CD15 (p &lt; 0.01) and CD11b (p &lt; 0.05) was significantly lower than that in M(2), but no significant difference was found as compared with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M(1) (p &gt; 0.05); MPO was significantly lower than that in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M(1) and M(2) (p &lt; 0.05); HLA-DR was significantly higher than that on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M(2) (p &lt; 0.05), but no significant difference was found as compared with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M(1) (p &gt; 0.05) </plain></SENT>
<SENT sid="11" pm="."><plain><z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB-II</z:e> did not express CD2, CD3, CD5 and CD8 (positive rate 0%, p &lt; 0.01) when compared with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e>; CD4 (p &lt; 0.05) and CD7 (p &lt; 0.01) were significantly lower than that in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain><z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB-II</z:e> did not express CD19 and CD20 (positive rate 0%, p &lt; 0.01) as compared with <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>; CD10, CD22 and cCD79a were significantly lower than that in <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> (p &lt; 0.05) </plain></SENT>
<SENT sid="13" pm="."><plain>CD117 (p = 0.0197) and MPO (p = 0.0085) were the two prognostic immunological antigens as regards the overall survival (OS) of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; CD117 (p = 0.003) was the single parameter in Cox regression </plain></SENT>
<SENT sid="14" pm="."><plain>It is concluded that <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB-II</z:e> expresses mainly myeloid antigen without or with little expression of lymphoid antigen </plain></SENT>
<SENT sid="15" pm="."><plain>Unique individual immunophenotypic features can be detected in patients with <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB-II</z:e> </plain></SENT>
<SENT sid="16" pm="."><plain>HLA-DR can be a specific parameter to distinguish the other subtypes of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="17" pm="."><plain>CD117 may be an independent prognostic immunological antigen as regards OS of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>